2025-08-11 - Analysis Report
Okay, here's an analysis of Teladoc Health Inc. (TDOC) based on the data provided.

## Teladoc Health Inc. (TDOC) Analysis

### 1. Performance vs. S&P 500 (VOO)

*   **Company Overview:** Teladoc Health Inc. is a telehealth and virtual healthcare company offering a range of services.
*   **Cumulative Return (TDOC):** -65.58%
*   **Cumulative Return (VOO):** 84.01%
*   **Relative Deviation:** -152.7
*   **Relative Deviation Percentile:** 0.3
*   **Analysis:** TDOC has significantly underperformed the S&P 500. The relative deviation of -152.7 indicates a substantial performance gap. The relative deviation percentile of 0.3 suggests that the current underperformance is near the worst levels observed historically relative to VOO.

**Alpha, Beta Analysis**

| Year       | CAGR     | MDD      | Alpha    | Beta   | Cap(B) |
|------------|----------|----------|----------|--------|--------|
| 2015-2017  | 76.0%    | 60.6%    | 74.0%    | 0.2    | 6.2    |
| 2016-2018  | 128.0%   | 59.3%    | 132.0%   | 0.0    | 8.8    |
| 2017-2019  | 176.0%   | 59.3%    | 154.0%   | 0.0    | 14.8   |
| 2018-2020  | 237.0%   | 64.0%    | 210.0%   | 0.0    | 35.3   |
| 2019-2021  | -83.0%   | 64.0%    | -132.0%  | 0.0    | 16.2   |
| 2020-2022  | -295.0%  | 81.3%    | -301.0%  | 0.0    | 4.2    |
| 2021-2023  | -488.0%  | 81.3%    | -508.0%  | -0.4   | 3.8    |
| 2022-2024  | -111.0%  | 81.3%    | -138.0%  | -0.6   | 1.6    |
| 2023-2025  | -36.0%   | 75.5%    | -85.0%   | -0.7   | 1.2    |

*   **CAGR:**  Shows strong growth in earlier periods, but significantly declines to negative values in recent years.
*   **MDD:**  High Maximum Drawdown values indicate significant risk and volatility.
*   **Alpha:**  Positive Alpha in earlier periods suggests outperformance relative to a benchmark, but turns negative in recent years, indicating underperformance.
*   **Beta:**  Low Beta values suggest that the stock is less sensitive to market movements, but the negative values in recent years indicate an inverse relationship with the market.
*   **Cap(B):**  Market capitalization generally decreases over time, reflecting a decline in the company's valuation.

### 2. Recent Stock Price Movement

*   **Current Price:** 6.96
*   **Previous Close:** 6.95
*   **Change:** 0.14
*   **5-Day Moving Average:** 6.966
*   **20-Day Moving Average:** 7.6995
*   **60-Day Moving Average:** 7.5945

*   **Analysis:** The current price is slightly above the previous close, indicating a minor positive change. However, the price is below both the 20-day and 60-day moving averages, suggesting a short-term downtrend.

### 3. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3323 (Low Risk)
*   **RSI:** 15.92 (Oversold)
*   **PPO:** -1.7133
*   **Hybrid Signal:** cash_69%_Sell 1.0% of holdings (16 shares - Caution - MRI:0.33)
*   **Delta_Previous_Relative_Divergence:** 0.2 (Positive - Short-term Increase)
*   **Expected Return:** -9893.8%

*   **Analysis:**
    *   The MRI suggests low market risk.
    *   The RSI of 15.92 indicates that the stock is heavily oversold, potentially signaling a possible, but not guaranteed, rebound.
    *   The PPO is negative, further confirming the downtrend.
    *   The hybrid signal suggests a cautionary stance, recommending a high cash position and a small reduction in holdings.
    *   The positive change in relative divergence indicates a potential short-term upward movement.
    *   The dramatically negative expected return suggests extremely poor long-term prospects compared to the S&P 500, according to the model used.
*   **Recent price change:** {'price': 6.96, 'previousClose': 6.95, 'change': 0.14}가 소폭 상승을 나타내지만, 전반적인 지표는 여전히 약세를 나타내고 있습니다.
*   **Issue:** The substantial negative expected return should be viewed with scrutiny, as it is an extreme outlier.

### 4. Recent News & Significant Events

*   **[2025-08-11]:** Major business developments, regulatory changes, or market events.
*   **[2025-08-09]:** Analyst discussions of recent performance and outlook.
*   **[2025-08-08]:** Notable stock volatility.
*   **[2025-08-10]:** Market experts highlight risks and opportunities.

*   **Analysis:** Recent news indicates significant activity surrounding Teladoc Health, including volatility and analyst scrutiny. This suggests that the company is undergoing substantial changes or facing challenges.

### 5. Recent Earnings Analysis

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-07-30 | -0.19 | 0.63 B$   |
| 2025-05-01 | -0.53 | 0.63 B$   |
| 2024-10-31 | -0.19 | 0.64 B$   |
| 2024-08-01 | -4.92 | 0.64 B$   |
| 2025-07-30 | -4.92 | 0.64 B$   |

*   **Analysis:**
    *   EPS (Earnings Per Share) has been negative for the reported periods, indicating a lack of profitability.
    *   Revenue has been relatively stable around $0.63-0.64 billion per quarter.
    *   The large negative EPS values in '2024-08-01' and '2025-07-30' (duplicated) suggest significant losses in those quarters, potentially due to one-time charges or other factors.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30   | $0.63B    | 69.85%        |
| 2025-03-31   | $0.63B    | 68.73%        |
| 2024-12-31   | $0.64B    | 70.50%        |
| 2024-09-30   | $0.64B    | 71.94%        |
| 2024-06-30   | $0.64B    | 70.73%        |

*   **Analysis:**
    *   Revenue has been consistent.
    *   Profit margins are high, around 70%, which is generally a positive sign.  However, these are *gross* profit margins, not net profit margins.  This means cost of revenue is being managed well, but it doesn't account for operating expenses.

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-06-30   | $1.42B    | -2.30%   |
| 2025-03-31   | $1.43B    | -6.52%   |
| 2024-12-31   | $1.49B    | -3.25%   |
| 2024-09-30   | $1.51B    | -2.21%   |
| 2024-06-30   | $1.50B    | -55.77%  |

*   **Analysis:**
    *   Equity has been relatively stable, but trending downward.
    *   ROE (Return on Equity) is negative, confirming the company is not generating profits from its equity. The large negative ROE in 2024-06-30 aligns with the large EPS loss reported in the earnings analysis, suggesting a particularly unprofitable quarter.

### 7. Overall Summary and Conclusion

Teladoc Health Inc. (TDOC) is currently facing significant challenges. It has substantially underperformed the S&P 500. While revenue is stable and gross profit margins are strong, the company is not profitable, as evidenced by negative EPS and ROE. Recent news indicates volatility and scrutiny. The technical indicators suggest the stock is oversold, potentially leading to a short-term rebound, but the overall trend is negative. The hybrid signal recommends a cautious approach. The extremely negative expected return is concerning and should be further investigated.

**Recommendation:**

Given the current financial performance, negative profitability metrics, and significant underperformance compared to the market, a **cautious or bearish outlook** is warranted. Investors should closely monitor the company's progress in improving profitability and addressing the challenges it faces. The seemingly oversold conditions may present a *speculative* short-term trading opportunity, but a long-term investment appears risky at this time.
